EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Singapore Institute of Advance (9G2) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Singapore Institute of Advance S$0.03, price S$0.03, upside -7.9%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SG · ISIN SGXE79544776

SI Thin data Sep 27, 2026

Singapore Institute of Advance

9G2 · SG

Low PriorityFair Value upside is limited and quality is weak.

·Fair value 0.0258 SGD · Fairly valued (−7.9%)
!Quality 36/100
!Expensive Growth (revenue 3y +4.4 %/yr)
!Loss-making · -157.8% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (1/10)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 23 out of 100
Watch Singapore Institute of Advance for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.1900 SGD 0.0250 SGD Fair Value 0.0258 SGD Feb 2024 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

31‑month range 0.0250 SGD – 0.1900 SGD · fair‑value band 0.0258 SGD – 0.0286 SGD · the 0.0280 SGD price screens above the 0.0258 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Singapore Institute of Advance in your weekly email

Every Wednesday you see whether Singapore Institute of Advance is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore.

Show more

Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore. The company offers medical diagnostics and treatments, including cancer-related diagnostics and theragnostic treatments, general diagnostics and health screening, and aesthetic services; and radiation therapy and medical oncology services comprise proton beam therapy, photon radiation therapy, and medical oncology services. It provides clinic and imaging services; manufactures medical research and clinical diagnostic instruments and supplies; and sells pharmaceuticals, surgical products, and consumables. Singapore Institute of Advanced Medicine Holdings Ltd. was incorporated in 2011 and is based in Singapore.

Stock analysis

Singapore Institute of Advance (9G2) currently trades at 0.0280 SGD, while our model-based Fair Value estimate is 0.0258 SGD, so the stock looks roughly fairly valued today (gap 8.5%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: 0.0258 SGD (bear) to 0.0286 SGD (bull), the price of 0.0280 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Singapore Institute of Advance reported revenue of 15.7M SGD in FY2025 versus 13.8M SGD in FY2022, a compound +4.4%/yr. Reported net income was −26.2M SGD in FY2025.

Key figures

Market cap 48.3M SGD (≈ $37.7M) · P/S ratio 2.99 · EPS (TTM) −0.0200 SGD · Net margin −158% · Return on equity −51.0% · Return on assets (EBIT) −12.3% · Operating margin −123% · Revenue (TTM) 16.2M SGD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −8%, 9G2 screens richer than that median.

Fair Value models

Bear 0.0258 SGD Fair Value 0.0258 SGD Bull 0.0286 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.0200 SGD 0.0200 SGD 0.0300 SGD 55
All 1 models by family
Asset-Based
NCAV (Graham) 0.0200 SGD 0.0200 SGD 0.0300 SGD 55

Open the full fair value analysis →

Notify me when 9G2 reaches fair value

Put 9G2 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 35 · Market factors (momentum, volatility) 23

Profitability 4
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 36
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 66
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−96.4% (2022) → −142.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 9G2, get fair value alerts →

Compare Singapore Institute of Advance with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −7.9% · Below median
Profitability
Return on assets −9.9% · Bottom 25%
Net margin (TTM) −157.8% · Bottom 25%
Operating margin (TTM) −123.5% · Bottom 25%
Growth and dividend
Revenue growth −0.1% · Below median
Balance sheet
Debt / equity 0.34× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.68× · Cheapest 25%
P/S (TTM) 2.33× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 33
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 31
HEALTH (low debt)83 · sector 89
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Singapore Institute of Advance · Fair Value
0.0258 SGD −8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Singapore Institute of Advance Fair Value". https://www.fairvalue-calculator.com/stock/9G2

Frequently asked questions

Is Singapore Institute of Advance (9G2) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.0258 SGD versus a price of 0.0280 SGD, about −8% upside (fairly valued).
What is the fair value of 9G2?
Our model-based fair value for Singapore Institute of Advance is 0.0258 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.0280 SGD.
What is the quality score of 9G2?
Singapore Institute of Advance has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Singapore Institute of Advance (9G2)?
Our model-based price target is the fair value of 0.0258 SGD (as of Sep 27, 2026) from 1 valuation models. Cautious scenario 0.0258 SGD, optimistic scenario 0.0286 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the Singapore Institute of Advance stock forecast for 2026?
Our models put fair value at 0.0258 SGD, about −8% upside versus a price of 0.0280 SGD (fairly valued). Cautious scenario 0.0258 SGD, optimistic scenario 0.0286 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of Singapore Institute of Advance (9G2)?
Singapore Institute of Advance reported trailing-twelve-month revenue of about 16.2M SGD (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Singapore Institute of Advance (9G2)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Singapore Institute of Advance it is 0.0258 SGD per share (as of Sep 27, 2026), against a price of 0.0280 SGD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Singapore Institute of Advance stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 9G2 trades above its calculated fair value: price 0.0280 SGD, fair value 0.0258 SGD, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9G2?
No. The price is what the market pays today (0.0280 SGD); the fair value is what the company's own numbers justify (0.0258 SGD). For Singapore Institute of Advance the two are 0.0022 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is Singapore Institute of Advance worth?
The market values Singapore Institute of Advance at about 48.3M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.0280 SGD; our models calculate a fair value of 0.0258 SGD per share.
What do the bullish and bearish scenarios say about 9G2?
Our models span a range for Singapore Institute of Advance: cautious scenario 0.0258 SGD, base 0.0258 SGD, optimistic 0.0286 SGD per share (as of Sep 27, 2026, price 0.0280 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Singapore Institute of Advance (9G2)?
Balance-sheet figures for Singapore Institute of Advance (as of Sep 27, 2026): return on equity −51.0%, debt of 0.34 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 9G2 from its 52-week high?
Singapore Institute of Advance trades at 0.0280 SGD, about 65% below its 52-week high of 0.0800 SGD and 12% above the low of 0.0250 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0258 SGD is for.
Which stocks are comparable to Singapore Institute of Advance?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Singapore Institute of Advance stock attractive at the current price?
The data as of Sep 27, 2026: price 0.0280 SGD, calculated fair value 0.0258 SGD (−8%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9G2 calculated?
We run Singapore Institute of Advance through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0258 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Singapore Institute of Advance itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Singapore Institute of Advance (9G2)?
The closing price on Oct 1, 2026 was 0.0280 SGD. Our model-based fair value is 0.0258 SGD, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Singapore Institute of Advance right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (0.0258 SGD to 0.0286 SGD), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Singapore Institute of Advance

How large is the market capitalisation of Singapore Institute of Advance (9G2)?
The market capitalisation of Singapore Institute of Advance is 48.3M SGD (≈ $37.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Singapore Institute of Advance (9G2)?
The price-to-sales ratio of Singapore Institute of Advance is 2.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Singapore Institute of Advance (9G2)?
Earnings per share at Singapore Institute of Advance are −0.0200 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Singapore Institute of Advance (9G2)?
The net margin of Singapore Institute of Advance is −158% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Singapore Institute of Advance (9G2)?
The return on equity (ROE) of Singapore Institute of Advance is −51.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Singapore Institute of Advance (9G2)?
On an EBIT basis the return on assets of Singapore Institute of Advance is −12.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Singapore Institute of Advance (9G2)?
The operating margin of Singapore Institute of Advance is −123% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Singapore Institute of Advance (9G2)?
Revenue at Singapore Institute of Advance is growing −0.1% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Singapore Institute of Advance (9G2) generate?
The free cash flow of Singapore Institute of Advance is −10.8M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Singapore Institute of Advance (9G2) carry?
The net debt of Singapore Institute of Advance is 25.4M SGD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Singapore Institute of Advance in the live analysis

One click puts Singapore Institute of Advance on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.